WO2017089595A1 - Solution comprising glycerophosphoric acid and magnesium salt thereof - Google Patents

Solution comprising glycerophosphoric acid and magnesium salt thereof Download PDF

Info

Publication number
WO2017089595A1
WO2017089595A1 PCT/EP2016/078910 EP2016078910W WO2017089595A1 WO 2017089595 A1 WO2017089595 A1 WO 2017089595A1 EP 2016078910 W EP2016078910 W EP 2016078910W WO 2017089595 A1 WO2017089595 A1 WO 2017089595A1
Authority
WO
WIPO (PCT)
Prior art keywords
solution
aqueous solution
polyol
glycerophosphoric acid
glycerophosphate
Prior art date
Application number
PCT/EP2016/078910
Other languages
French (fr)
Inventor
Pierre VAN LOCKLAND
Original Assignee
Fontus Health Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fontus Health Ltd filed Critical Fontus Health Ltd
Publication of WO2017089595A1 publication Critical patent/WO2017089595A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention relates to magnesium glycerophosphate oral solutions, in particular to aqueous solutions comprising magnesium glycerophosphate, a polyol such as glycerol and glycerophosphoric acid.
  • a stable and efficacious product can be formed suitable for delivering Mg to a patient suffering from hypomagnesaemia without forming precipitates characteristic of current commercial products.
  • Magnesium glycerophosphate is a white, odourless, amorphous powder with a somewhat bitter taste and sparing water solubility. Magnesium glycerophosphate is a preparation used to treat conditions such as hypomagnesaemia. In particular, it is used to prevent recurrence of magnesium hypomagnesaemia in people who have already been treated for this condition.
  • hypomagnesaemia is the presence of abnormally low levels of serum magnesium. It is relatively common, being estimated to affect 2.5% to 15% of the general population and up to 65%> of patients in intensive care settings. However, most patients with hypomagnesaemia are asymptomatic; symptoms are not usually seen until serum magnesium concentration falls below 0.5 mmol/litre.
  • hypomagnesaemia causes inadequate dietary intake, reduced intestinal absorption and increased renal excretion.
  • Magnesium salts are not well absorbed from the gastrointestinal tract, with most being absorbed in the small intestine. Excessive losses in diarrhoea, stomata or fistulae are reportedly the most common causes of hypomagnesaemia. Small bowel bypass surgery and diseases that cause malabsorption can also lead to hypomagnesaemia.
  • Magnesium is primarily excreted by the kidneys. Inherited renal tubular reabsorption defects that result in increased excretion of magnesium, such as Gitelman's syndrome, are associated with hypomagnesaemia. Other conditions associated with hypomagnesaemia include malnutrition, anorexia nervosa, chronic alcoholism, total parenteral nutrition, acute pancreatitis, diabetic ketoacidosis, hypersecretion of aldosterone and lactation.
  • Certain drug treatments including diuretics, antibiotics (such as amphotericin B and aminoglycosides), immunosuppressants and chemotherapy drugs (particularly cisplatin) have been associated with hypomagnesaemia.
  • antibiotics such as amphotericin B and aminoglycosides
  • immunosuppressants and chemotherapy drugs (particularly cisplatin) have been associated with hypomagnesaemia.
  • the number of cases of hypomagnesaemia associated with proton pump inhibitors reported in the literature is increasing.
  • hypomagnesaemia The signs and symptoms of hypomagnesaemia include neuromuscular, cardiovascular and metabolic features. Neuromuscular effects include muscle weakness, ataxia, tremor and spasms of the feet and hands. Severe
  • hypomagnesaemia can cause seizures (especially in children) and coma.
  • Cardiovascular effects include arrhythmias and electrocardiogram (ECG) abnormalities.
  • hypocalcaemia is often associated with other biochemical and electrolyte abnormalities, such as hypocalcaemia, hypokalaemia, hyponatraemia and metabolic acidosis. Some of the symptoms seen in hypomagnesaemia may relate to these associated abnormalities.
  • magnesium sulfate For symptomatic hypomagnesaemia, intravenous infusion of magnesium sulfate is initially used and oral magnesium supplements can be given subsequently to prevent recurrence. Intramuscular injection of magnesium sulfate is another option for initial treatment but is painful. Other sources advise that oral magnesium may be used as first-line treatment, the selection of route of administration being influenced by severity and oral tolerability,
  • the present invention relates to oral magnesium preparations, in particular those in solution form.
  • Mg can be administered orally via a tablet or solution.
  • magnesium glycerophosphate is essentially insoluble in water is a problem for any liquid solution, in particular aqueous solution. It also affects bioavailability.
  • magnesium glycerophosphate In order to improve the solubility of the magnesium glycerophosphate in water, it is often formulated with glycerophosphoric acid, citric acid or an alkali citrate. However, on standing a solution containing these ingredients forms a precipitate. After storage therefore, current magnesium glycerophosphate aqueous solutions contain unacceptable deposits and are unsuitable for oral administration. Without wishing to be limited by theory, it is suggested that the deposits are magnesium compounds.
  • the present inventors sought a way of producing solutions of magnesium glycerophosphate without the issue of deposits on storage.
  • the inventors have surprisingly found that this problem can be solved by an aqueous solution as claimed in claim 1 in which the magnesium glycerophosphate is combined with a polyol such as glycerol and glycerophosphoric acid.
  • the relative amounts of these components gives rise to a particularly advantageous solution in which deposits are avoided.
  • the invention provides an aqueous solution comprising magnesium glycerophosphate, a polyol such as glycerol and
  • the invention provides an aqueous solution comprising glycerophosphate, a polyol such as glycerol and glycerophosphoric acid for use in the treatment or prevention of hypomagnesaemia.
  • the invention provides a method of treating or preventing hypomagnesaemia comprising administering to a patient in need therefor an effective amount of an aqueous solution of glycerophosphate, a polyol such as glycerol and glycerophosphoric acid.
  • the invention provides use of an aqueous solution of glycerophosphate, a polyol such as glycerol and glycerophosphoric acid in the manufacture of a medicament for the treatment of hypomagnesaemia.
  • the invention provides a process for the preparation of an aqueous solution as hereinbefore defined comprising dissolving magnesium glycerophosphate in glycerophosphoric acid in water to form a solution and subsequently adding a polyol such as glycerol.
  • the composition of the invention is an aqueous solution.
  • the components of the solution therefore dissolve in the water present.
  • the invention does not therefore relate to a suspension or emulsion.
  • the solution is preferably clear. It may have a pH of 1.5 to 5, such as 2 to 4.
  • the aqueous solution is suitable for pharmaceutical administration.
  • the solution of the invention comprises a minimum of three components.
  • the composition of the invention consists of the three components recited above as well as water.
  • Magnesium glycerophosphate is a compound of formula (I)
  • the amount of magnesium glycerophosphate in the aqueous solution of the invention may be 5 to 50 wt%, preferbly 10 to 30 wt%, such as 12 to 25 wt%, especially 15 to 20 wt%, such as 16 to 18 wt%.
  • magnesium glycerophosphate may form 25 to 50 wt% of the composition, such as 30 to 45 wt%, preferably 35 to 45 wt%.
  • the amount of magnesium glycerophosphate present is preferably adjusted to deliver between 100 and 150 mg of Mg per 5 ml of the solution, such as 110 to 140 mg/5 ml of solution.
  • the magnesium glycerophosphate itself may contain 11 to 12.5wt% of Mg. Mg preferably forms around 11.5 wt% of the magnesium
  • a preferred amount is 2 to 10 mmol Mg/5 ml of solution, such as 5 mmol Mg/5ml.
  • glycerophosphoric acid In order to dissolve the magnesium glycerophosphate to create a solution, it is necessary to add glycerophosphoric acid. It is preferred if the glycerophosphoric acid is provided in an aqueous solution.
  • the amount of glycerophosphoric acid in the solution can vary. Suitable concentrations include a 5 to 50 wt% solution of glycerophosphoric acid in water, such as a 10 to 30 wt% solution, preferably a 15 to
  • the more important figure is the amount of glycerophosphoric acid relative to the amount of magnesium glycerophosphate. It is preferred if there is at least an equimolar molar amount of glycerophosphoric acid relative to magnesium glycerophosphate, i.e. the molar ratio is 1 : 1 or there is an excess of
  • glycerophosphoric acid e.g. a molar ratio of 1 : 1 to 1 :2 such as 1 : 1 to 1.5, magnesium glycerophosphate to glycerophosphoric acid.
  • the molar ratio of magnesium glycerophosphate to glycerophosphoric acid is 1.0 to 1.0 such as 1.00: 1.00 or 1.00:(1.00 to 1.05, such as 1.00 to 1.01).
  • the glycerophosphoric acid content in the solution of the invention might be 5 to 40 wt%, such as 6 to 30 wt%, ideally 7 to 20 wt%, such as 10 to 15 wt%.
  • the glycerophosphoric acid may form 20 to 40 wt% , such as 25 to 35 wt% of the composition.
  • Water preferably forms at least 40 wt% of the solution, such as at least 45 wt%, ideally at least 50 wt%, e.g. the balance of the solution. Water is preferably supplied only as part of the glycerophosphoric acid solution.
  • magnesium glycerophosphate and glycerophosphoric acid alone does not result in a solution that is free of deposits.
  • the inventors have found that the addition of a polyol, in particular glycerol, gives rise to a composition that remains in solution on storage. It is the combination of the components that solves the problem. It is the presence of the polyol that appears to prevent deposits forming.
  • glycerol acts as a preservative and therefore the addition of other preservative agents can be avoided.
  • the composition of the invention is administered orally.
  • the presence of a polyol provides the composition with a sweet taste. This means that taste masking agents or flavors that might otherwise be needed to make an oral solution palatable can also be avoided.
  • glycerol is a liquid and can itself act to dissolve the active ingredients present. This makes formulation of the product easier relative to adding other polyols which are often powders.
  • the amount of polyol present can vary. Once sufficient polyol is present to allow a solution to be formed (and hence to prevent deposits forming in the solution), any excess polyol acts as a preservative and sweetener for the formulation.
  • the amount of a polyol such as glycerol present is preferably 5 to 40 wt% of the solution, such as 7 to 30 wt%, preferably 8 to 20 wt%, ideally 10 to 18 wt%.
  • polyols may form 20 to 40 wt%, such as 25 to 35 wt% of the composition.
  • Polyols of use in the solution are compounds comprising 10 carbon atoms or less and at least two hydroxyl groups such as glycerol.
  • the polyol is a liquid at standard ambient temperature (25 °C).
  • Preferred polyols contain C, H and O atoms only.
  • the polyol comprises 2 to 6 C atoms, such as 3 to 5 C atoms.
  • Preferred polyols have 2 to 4 OH groups such as 3 OH groups. Mixtures of polyols may also be used.
  • the solution of the invention does not give rise to any deposits upon standing, e.g. at 23°C for 3 months.
  • the solution of the invention can be prepared simply by mixing the components in water.
  • the glycerophosphoric acid solution is added to magnesium glycerophosphate before the glycerol is added.
  • glycerophosphate is present so that enough glycerophosphoric acid is added to ensure the formation of a solution.
  • an assay of magnesium glycerophosphate can be carried out as a first step.
  • a suitable amount of magnesium glycerophosphate can be added to the glycerophosphoric acid solution (such as a 20 wt% solution in water) to ensure that there is a 1 : 1 ratio of these components or to ensure that there is an excess of the acid. It may be necessary to assay the glycerophosphoric acid solution to make sure the
  • glycerophosphoric acid content of the solution is known accurately.
  • the polyol such as glycerol can be added.
  • Polyol is typically added to ensure a desired final concentration of Mg in the solution, such as 25 mg of Mg/ml.
  • the inventino provides an aqueous solution comprising:
  • administration orally when a patient needs it can be stored in a refrigerator and may be stored in the dark.
  • the amount of Mg in the solution can be readily adjusted by changing the amount of the active ingredient present so that different dosage solutions can be designed.
  • Dosages of the solution to be given to a patient will be determined by a physician assessing the patient in question. To prevent recurrence of
  • oral magnesium may be given in a dose of 300 to 600 mg/day.
  • a typical dose might be 24 mmol Mg 2+ daily.
  • solutions of the invention may contain small amounts (e.g. less than 2 wt%) of standard additives but preferably the solution of the invention consists of water, polyols, glycerophosphoric acid and magnesium glycerophosphate.
  • the solution is suitable for treating or preventing hypomagnesaemia.
  • the solution may be given to a patient at risk of developing hypomagnesaemia or to a patient with hypomagnesaemia.
  • the solution is ideally for oral administration.
  • composition comprising the following:
  • MGP contains between 11 and 12.5 wt%, such as 11.5 wt% Magnesium(Mg).
  • the solubility of MGP in water (20°C) is 8.0 gram/1 OOmL.
  • the solution of the invention contains 21.13 g of MGP per 100ml and hence contains almost three times the active content than the conventional solubility of MGP in water. Solubility of MGP is hence markedly enhanced by dissolving MGP in the acid and glycerol.
  • MGP aqueous solutions were acidified with a 20 wt% test concentration of citric acid, phosphoric acid and glycerophophoric acid.
  • the molar ratio of MGP to acid was set at 1 : 1.
  • the MGP content of the solutions was measured to give 21 13 mg MGP per 10 ml.
  • Glycerol was therefore selected as an additional medium to dilute MGP solutions.
  • Mg/5mL with glycerol was successful and resulted in a physically stable clear aqueous MGP solutions. This solution was stored at room temperature for 2 months without the formation of deposits.
  • the invention provides an aqueous solution comprising magnesium glycerophosphate, a polyol such as glycerol and an acid selected from citric acid and phosphoric acid.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

An aqueous solution comprising magnesium glycerophosphate, a polyol such as glycerol and glycerophosphoric acid.

Description

SOLUTION COMPRISING GLYCEROPHOSPHORIC ACID AND MAGNESIUM
SALT THEREOF
This invention relates to magnesium glycerophosphate oral solutions, in particular to aqueous solutions comprising magnesium glycerophosphate, a polyol such as glycerol and glycerophosphoric acid.
By combining these three materials in an aqueous solution, a stable and efficacious product can be formed suitable for delivering Mg to a patient suffering from hypomagnesaemia without forming precipitates characteristic of current commercial products.
Background
Magnesium glycerophosphate is a white, odourless, amorphous powder with a somewhat bitter taste and sparing water solubility. Magnesium glycerophosphate is a preparation used to treat conditions such as hypomagnesaemia. In particular, it is used to prevent recurrence of magnesium hypomagnesaemia in people who have already been treated for this condition.
Hypomagnesaemia is the presence of abnormally low levels of serum magnesium. It is relatively common, being estimated to affect 2.5% to 15% of the general population and up to 65%> of patients in intensive care settings. However, most patients with hypomagnesaemia are asymptomatic; symptoms are not usually seen until serum magnesium concentration falls below 0.5 mmol/litre.
Causes of hypomagnesaemia include inadequate dietary intake, reduced intestinal absorption and increased renal excretion. Magnesium salts are not well absorbed from the gastrointestinal tract, with most being absorbed in the small intestine. Excessive losses in diarrhoea, stomata or fistulae are reportedly the most common causes of hypomagnesaemia. Small bowel bypass surgery and diseases that cause malabsorption can also lead to hypomagnesaemia.
Magnesium is primarily excreted by the kidneys. Inherited renal tubular reabsorption defects that result in increased excretion of magnesium, such as Gitelman's syndrome, are associated with hypomagnesaemia. Other conditions associated with hypomagnesaemia include malnutrition, anorexia nervosa, chronic alcoholism, total parenteral nutrition, acute pancreatitis, diabetic ketoacidosis, hypersecretion of aldosterone and lactation.
Certain drug treatments including diuretics, antibiotics (such as amphotericin B and aminoglycosides), immunosuppressants and chemotherapy drugs (particularly cisplatin) have been associated with hypomagnesaemia. The number of cases of hypomagnesaemia associated with proton pump inhibitors reported in the literature is increasing.
The signs and symptoms of hypomagnesaemia include neuromuscular, cardiovascular and metabolic features. Neuromuscular effects include muscle weakness, ataxia, tremor and spasms of the feet and hands. Severe
hypomagnesaemia can cause seizures (especially in children) and coma.
Cardiovascular effects include arrhythmias and electrocardiogram (ECG) abnormalities.
Hypomagnesaemia is often associated with other biochemical and electrolyte abnormalities, such as hypocalcaemia, hypokalaemia, hyponatraemia and metabolic acidosis. Some of the symptoms seen in hypomagnesaemia may relate to these associated abnormalities.
For symptomatic hypomagnesaemia, intravenous infusion of magnesium sulfate is initially used and oral magnesium supplements can be given subsequently to prevent recurrence. Intramuscular injection of magnesium sulfate is another option for initial treatment but is painful. Other sources advise that oral magnesium may be used as first-line treatment, the selection of route of administration being influenced by severity and oral tolerability,
The present invention relates to oral magnesium preparations, in particular those in solution form. In order to introduce Mg into the diet of patients with hypomagnesaemia Mg can be administered orally via a tablet or solution. However, the fact that magnesium glycerophosphate is essentially insoluble in water is a problem for any liquid solution, in particular aqueous solution. It also affects bioavailability.
In order to improve the solubility of the magnesium glycerophosphate in water, it is often formulated with glycerophosphoric acid, citric acid or an alkali citrate. However, on standing a solution containing these ingredients forms a precipitate. After storage therefore, current magnesium glycerophosphate aqueous solutions contain unacceptable deposits and are unsuitable for oral administration. Without wishing to be limited by theory, it is suggested that the deposits are magnesium compounds.
The present inventors sought a way of producing solutions of magnesium glycerophosphate without the issue of deposits on storage. The inventors have surprisingly found that this problem can be solved by an aqueous solution as claimed in claim 1 in which the magnesium glycerophosphate is combined with a polyol such as glycerol and glycerophosphoric acid. In particular, the relative amounts of these components gives rise to a particularly advantageous solution in which deposits are avoided.
Summary of Invention Thus viewed from one aspect the invention provides an aqueous solution comprising magnesium glycerophosphate, a polyol such as glycerol and
glycerophosphoric acid.
Viewed from another aspect the invention provides an aqueous solution comprising glycerophosphate, a polyol such as glycerol and glycerophosphoric acid for use in the treatment or prevention of hypomagnesaemia.
Viewed from another aspect the invention provides a method of treating or preventing hypomagnesaemia comprising administering to a patient in need therefor an effective amount of an aqueous solution of glycerophosphate, a polyol such as glycerol and glycerophosphoric acid.
Viewed from another aspect the invention provides use of an aqueous solution of glycerophosphate, a polyol such as glycerol and glycerophosphoric acid in the manufacture of a medicament for the treatment of hypomagnesaemia.
Viewed from another aspect the invention provides a process for the preparation of an aqueous solution as hereinbefore defined comprising dissolving magnesium glycerophosphate in glycerophosphoric acid in water to form a solution and subsequently adding a polyol such as glycerol. Detailed description of the invention
The composition of the invention is an aqueous solution. The components of the solution therefore dissolve in the water present. The invention does not therefore relate to a suspension or emulsion. The solution is preferably clear. It may have a pH of 1.5 to 5, such as 2 to 4.
The aqueous solution is suitable for pharmaceutical administration. Along with water, the solution of the invention comprises a minimum of three components. In some embodiment the composition of the invention consists of the three components recited above as well as water.
Magnesium glycerophosphate is a compound of formula (I)
Figure imgf000005_0001
The amount of magnesium glycerophosphate in the aqueous solution of the invention may be 5 to 50 wt%, preferbly 10 to 30 wt%, such as 12 to 25 wt%, especially 15 to 20 wt%, such as 16 to 18 wt%. In terms of dry weight (i.e. based on the components without water), magnesium glycerophosphate may form 25 to 50 wt% of the composition, such as 30 to 45 wt%, preferably 35 to 45 wt%.
The amount of magnesium glycerophosphate present is preferably adjusted to deliver between 100 and 150 mg of Mg per 5 ml of the solution, such as 110 to 140 mg/5 ml of solution. The magnesium glycerophosphate itself may contain 11 to 12.5wt% of Mg. Mg preferably forms around 11.5 wt% of the magnesium
glycerophosphate.
In molar terms, a preferred amount is 2 to 10 mmol Mg/5 ml of solution, such as 5 mmol Mg/5ml.
In order to dissolve the magnesium glycerophosphate to create a solution, it is necessary to add glycerophosphoric acid. It is preferred if the glycerophosphoric acid is provided in an aqueous solution. The amount of glycerophosphoric acid in the solution can vary. Suitable concentrations include a 5 to 50 wt% solution of glycerophosphoric acid in water, such as a 10 to 30 wt% solution, preferably a 15 to
25 wt% solution, e.g. 20 wt% solution.
The more important figure is the amount of glycerophosphoric acid relative to the amount of magnesium glycerophosphate. It is preferred if there is at least an equimolar molar amount of glycerophosphoric acid relative to magnesium glycerophosphate, i.e. the molar ratio is 1 : 1 or there is an excess of
glycerophosphoric acid, e.g. a molar ratio of 1 : 1 to 1 :2 such as 1 : 1 to 1.5, magnesium glycerophosphate to glycerophosphoric acid. Especially preferably, the molar ratio of magnesium glycerophosphate to glycerophosphoric acid is 1.0 to 1.0 such as 1.00: 1.00 or 1.00:(1.00 to 1.05, such as 1.00 to 1.01).
Hence, the glycerophosphoric acid content in the solution of the invention might be 5 to 40 wt%, such as 6 to 30 wt%, ideally 7 to 20 wt%, such as 10 to 15 wt%. In terms of dry weight, the glycerophosphoric acid may form 20 to 40 wt% , such as 25 to 35 wt% of the composition.
Water preferably forms at least 40 wt% of the solution, such as at least 45 wt%, ideally at least 50 wt%, e.g. the balance of the solution. Water is preferably supplied only as part of the glycerophosphoric acid solution.
The use however of magnesium glycerophosphate and glycerophosphoric acid alone does not result in a solution that is free of deposits. The inventors have found that the addition of a polyol, in particular glycerol, gives rise to a composition that remains in solution on storage. It is the combination of the components that solves the problem. It is the presence of the polyol that appears to prevent deposits forming.
Moreover, the use of glycerol in the aqueous solution of the invention is advantageous because glycerol acts as a preservative and therefore the addition of other preservative agents can be avoided. Moreover, the composition of the invention is administered orally. The presence of a polyol provides the composition with a sweet taste. This means that taste masking agents or flavors that might otherwise be needed to make an oral solution palatable can also be avoided. As a further benefit, glycerol is a liquid and can itself act to dissolve the active ingredients present. This makes formulation of the product easier relative to adding other polyols which are often powders. For the reasons above, the amount of polyol present can vary. Once sufficient polyol is present to allow a solution to be formed (and hence to prevent deposits forming in the solution), any excess polyol acts as a preservative and sweetener for the formulation.
The amount of a polyol such as glycerol present is preferably 5 to 40 wt% of the solution, such as 7 to 30 wt%, preferably 8 to 20 wt%, ideally 10 to 18 wt%. In terms of dry weight, polyols may form 20 to 40 wt%, such as 25 to 35 wt% of the composition. Ideally there is more magnesium glycerophosphate than polyol in terms of wt%.
Polyols of use in the solution are compounds comprising 10 carbon atoms or less and at least two hydroxyl groups such as glycerol. Preferably the polyol is a liquid at standard ambient temperature (25 °C). Preferred polyols contain C, H and O atoms only. Preferably the polyol comprises 2 to 6 C atoms, such as 3 to 5 C atoms. Preferred polyols have 2 to 4 OH groups such as 3 OH groups. Mixtures of polyols may also be used.
Advantageously, the solution of the invention does not give rise to any deposits upon standing, e.g. at 23°C for 3 months.
The solution of the invention can be prepared simply by mixing the components in water. In one embodiment, the glycerophosphoric acid solution is added to magnesium glycerophosphate before the glycerol is added.
In more detail however, it is important to know how much magnesium
glycerophosphate is present so that enough glycerophosphoric acid is added to ensure the formation of a solution. Thus, as a first step an assay of magnesium glycerophosphate can be carried out. Using the result of that assay, a suitable amount of magnesium glycerophosphate can be added to the glycerophosphoric acid solution (such as a 20 wt% solution in water) to ensure that there is a 1 : 1 ratio of these components or to ensure that there is an excess of the acid. It may be necessary to assay the glycerophosphoric acid solution to make sure the
glycerophosphoric acid content of the solution is known accurately.
Once the dissolution process has been carried out and a clear solution obtained, the polyol such as glycerol can be added. Polyol is typically added to ensure a desired final concentration of Mg in the solution, such as 25 mg of Mg/ml. Viewed from another aspect the inventino provides an aqueous solution comprising:
(i) 5 to 40 wt%, preferably 7 to 20 wt%, such as 10 to 15 wt%
glycerophosphoric acid;
(ii) 5 to 50 wt%, preferably 10 to 30 wt%, especially 15 to 20 wt%
magnesium glycerophosphate
(iii) at least 40 wt% water; and
(iv) 5 to 40 wt%, preferably 8 to 20 wt%, preferably 10 to 18 wt% polyol. The solution is preferably stored in an airtight container ready for
administration orally when a patient needs it. It can be stored in a refrigerator and may be stored in the dark.
It will be appreciated that the amount of Mg in the solution can be readily adjusted by changing the amount of the active ingredient present so that different dosage solutions can be designed.
Dosages of the solution to be given to a patient will be determined by a physician assessing the patient in question. To prevent recurrence of
hypomagnesaemia in adults for example, oral magnesium may be given in a dose of 300 to 600 mg/day. A typical dose might be 24 mmol Mg2+ daily.
The solutions of the invention may contain small amounts (e.g. less than 2 wt%) of standard additives but preferably the solution of the invention consists of water, polyols, glycerophosphoric acid and magnesium glycerophosphate.
The solution is suitable for treating or preventing hypomagnesaemia. Thus, the solution may be given to a patient at risk of developing hypomagnesaemia or to a patient with hypomagnesaemia. The solution is ideally for oral administration.
The invention will now be described with reference to the following non- limiting examples.
Example 1
A composition is prepared comprising the following:
Per 100ml: Component Per 100 ml batch g g
Magn. Glycerophosphate (MGP) 21,13 (0.1 mol) g
Glycerophosphoric acid 20 wt% in water 86,01 (0.1 mol) g
Glycerol 17,00 g
Commercially supplied, MGP contains between 11 and 12.5 wt%, such as 11.5 wt% Magnesium(Mg). For MGP containing 11.5 wt%, Mg, 243 mg Mg/lOml means (243/11 ,5)* 100=2113 mg MGP per 10 ml.
According to the literature, the solubility of MGP in water (20°C) is 8.0 gram/1 OOmL. As will immediately be clear, the solution of the invention contains 21.13 g of MGP per 100ml and hence contains almost three times the active content than the conventional solubility of MGP in water. Solubility of MGP is hence markedly enhanced by dissolving MGP in the acid and glycerol.
There are commercial formulations however, that claim MGP concentration of 1056.52 mg MGP/5mL. We tested this concentration of MGP in water and whilst initially clear MGP solutions were formed, the clear MGP test solutions
demonstrated precipitation/crystallization of unknown, previously dissolved material after 2-3 days storage at room temperature.
The use therefore of water alone as a solvent was confirmed as inappropriate.
With reference to enhancement of MGP solubility in dilute acids, MGP aqueous solutions were acidified with a 20 wt% test concentration of citric acid, phosphoric acid and glycerophophoric acid. The molar ratio of MGP to acid was set at 1 : 1. The MGP content of the solutions was measured to give 21 13 mg MGP per 10 ml.
On storage, all test formulations still showed precipitation/crystallization of unknown, previously dissolved material after 2-3 days storage at room temperature.
Glycerol was therefore selected as an additional medium to dilute MGP solutions.
Diluting 1 : 1 molar ratio MGP/glycerophosphoric acid solutions to 5.0 mmol
Mg/5mL with glycerol was successful and resulted in a physically stable clear aqueous MGP solutions. This solution was stored at room temperature for 2 months without the formation of deposits.
Results from a subsequently performed 3 months stability study confirmed that this formulation remains clear and stable (Mg assay, microbial), solutions were stored at ICH conditions 25 °C and 5°C.
Viewed from another aspect, the invention provides an aqueous solution comprising magnesium glycerophosphate, a polyol such as glycerol and an acid selected from citric acid and phosphoric acid.
All discussion above, e.g. percentages of acid, presented in terms of glycerophosphoric acid, can be applied to the citric acid and phosphoric acid embodiment.

Claims

Claims 1. An aqueous solution comprising magnesium glycerophosphate, a polyol such as glycerol and glycerophosphoric acid.
2. An aqueous solution as claimed in any preceding claim in which the glycerophosphoric acid content in the solution is 7 to 20 wt%, such as 10 to 15 wt%.
3. An aqueous solution as claimed in any preceding claim in which the amount of magnesium glycerophosphate is 10 to 30 wt%, especially 15 to 20 wt%.
4. An aqueous solution as claimed in any preceding claim in which the solution comprises between 100 and 150 mg of Mg per 5 ml of the solution.
5. An aqueous solution as claimed in any preceding claim in which water forms at least 40 wt% of the solution, e.g. balance water. 6. An aqueous solution as claimed in any preceding claim in which the amount of polyol is 8 to 20 wt%, preferably 10 to 18 wt%.
7. An aqueous solution as claimed in any preceding claim in which the polyol is a liquid at standard ambient temperature.
8. An aqueous solution as claimed in any preceding claim in which the polyol comprises 2 to 6 C atoms, such as 3 to 5 C atoms.
9. An aqueous solution as claimed in any preceding claim in which the polyol has 2 to 4 OH groups, such as 3 OH groups.
10. An aqueous solution as claimed in any preceding claim in which the molar ratio of magnesium glycerophosphate to glycerophosphoric acid is 1 : 1 or in which there is an excess molar amount of glycerophosphoric acid. 11. An aqueous solution consisting of magnesium glycerophosphate, a polyol such as glycerol and glycerophosphoric acid.
An aqueous solution as claimed in any preceding claim comprising (i) 5 to 40 wt%, preferably 7 to 20 wt%, such as 10 to 15 wt%
glycerophosphoric acid;
(ii) 5 to 50 wt%, preferably 10 to 30 wt%, especially 15 to 20 wt%
magnesium glycerophosphate
(iii) at least 40 wt% water; and
(iv) 5 to 40 wt%, preferably 8 to 20 wt%, preferably 10 to 18 wt% polyol.
13. An aqueous solution as claimed in any preceding claim comprising:
glycerophosphoric acid and magnesium glycerophosphate in a 1 : 1 molar ratio, at least 40 wt% water; and glycerol.
14. An aqueous solution comprising glycerophosphate, a polyol such as glycerol and glycerophosphoric acid for use in the treatment or prevention of
hypomagnesaemia.
15. A method of treating or preventing hypomagnesaemia comprising administering to a patient in need therefor an effective amount of an aqueous solution of glycerophosphate, a polyol such as glycerol and glycerophosphoric
16. Use of an aqueous solution of glycerophosphate, a polyol such as glycerol and glycerophosphoric acid in the manufacture of a medicament for the treatment of hypomagnesaemia.
PCT/EP2016/078910 2015-11-26 2016-11-25 Solution comprising glycerophosphoric acid and magnesium salt thereof WO2017089595A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1520902.6 2015-11-26
GB1520902.6A GB2544782B (en) 2015-11-26 2015-11-26 Solution

Publications (1)

Publication Number Publication Date
WO2017089595A1 true WO2017089595A1 (en) 2017-06-01

Family

ID=55177297

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/078910 WO2017089595A1 (en) 2015-11-26 2016-11-25 Solution comprising glycerophosphoric acid and magnesium salt thereof

Country Status (2)

Country Link
GB (1) GB2544782B (en)
WO (1) WO2017089595A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119390723A (en) * 2024-12-31 2025-02-07 安徽艾立德制药有限公司 Amorphous material of magnesium glycerophosphate and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2502735A1 (en) * 1975-01-23 1976-08-05 Pfrimmer & Co J INFUSION SOLUTIONS WITH SALT OF GLYCEROPHOSPHATE
EP0700681A1 (en) * 1993-04-30 1996-03-13 The Green Cross Corporation Nutritional transfusion for peripheral vein administration
EP1570851A1 (en) * 2002-12-10 2005-09-07 Masaya Tanaka Skin material for external use and antiprutiric agent for external use and wrinkle-reducing instrument using the same
EP1952801A1 (en) * 2005-11-25 2008-08-06 "WDS" Company Oral cavity care curative and prophylactic composition
WO2010131994A1 (en) * 2009-05-15 2010-11-18 Obshchestvo S Ogranichennoj Otvetstvennost'yu "Wds" Medicine for dental diseases prophylaxis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA012247B1 (en) * 2008-07-07 2009-08-28 Общество С Ограниченной Ответственностью "Вдс" Curative and prophylactic composition for oral cavity care

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2502735A1 (en) * 1975-01-23 1976-08-05 Pfrimmer & Co J INFUSION SOLUTIONS WITH SALT OF GLYCEROPHOSPHATE
EP0700681A1 (en) * 1993-04-30 1996-03-13 The Green Cross Corporation Nutritional transfusion for peripheral vein administration
EP1570851A1 (en) * 2002-12-10 2005-09-07 Masaya Tanaka Skin material for external use and antiprutiric agent for external use and wrinkle-reducing instrument using the same
EP1952801A1 (en) * 2005-11-25 2008-08-06 "WDS" Company Oral cavity care curative and prophylactic composition
WO2010131994A1 (en) * 2009-05-15 2010-11-18 Obshchestvo S Ogranichennoj Otvetstvennost'yu "Wds" Medicine for dental diseases prophylaxis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "TRIPHOSMAG : la fiche complète", 23 July 2015 (2015-07-23), XP055210042, Retrieved from the Internet <URL:http://medicament.comprendrechoisir.com/medicament/voir/24080/triphosmag> [retrieved on 20150828] *
NICE: "Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate", 29 January 2013 (2013-01-29), XP055330859, Retrieved from the Internet <URL:https://www.nice.org.uk/guidance/esuom4/resources/preventing-recurrent-hypomagnesaemia-oral-magnesium-glycerophosphate-1503234975394501> [retrieved on 20161221] *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119390723A (en) * 2024-12-31 2025-02-07 安徽艾立德制药有限公司 Amorphous material of magnesium glycerophosphate and preparation method thereof

Also Published As

Publication number Publication date
GB2544782A (en) 2017-05-31
GB201520902D0 (en) 2016-01-13
GB2544782B (en) 2020-07-15

Similar Documents

Publication Publication Date Title
CN106659711A (en) Durable preparation of an injectable of melatonin exhibiting long-term stability
JP2018150359A (en) Citrate-rich calcium and magnesium supplements and their use
WO2006130027A1 (en) Aqueous oral liquid vitamin supplements containing stabilized vitamin c and metal ions
JP2021523202A (en) Oral solution preparation
US20140147519A1 (en) Migraine Treatment
WO2017089595A1 (en) Solution comprising glycerophosphoric acid and magnesium salt thereof
US11135162B2 (en) Pharmaceutical composition in the form of an aqueous solution, 1A syrup, containing inosine pranobex and zinc gluconate and a method of preparation thereof
KR20190087039A (en) Oral emulsion formulation comprising Risedronic acid or its salts and vitamin D and the method for preparation thereof
RU2778647C2 (en) Pharmaceutical composition in form of aqueous solution, preferably syrup, containing inosine pranobex and zinc gluconate, and its production method
JP7308186B2 (en) Calcium supplement composition
EP3678498B1 (en) Composition for calcium supplementation
RU2237478C2 (en) Antimicrobial pharmaceutical composition
US20230082870A1 (en) Composition for calcium supplementation
HK40022725A (en) Composition for calcium supplementation
HK40022725B (en) Composition for calcium supplementation
EA042006B1 (en) COMPOSITION AS A CALCIUM SUPPLEMENT
JP2002538075A (en) Synthetic composition for the treatment and / or prevention of overweight and use thereof
HK1212166B (en) Citrate-rich calcium-magnesium supplement and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16801507

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16801507

Country of ref document: EP

Kind code of ref document: A1